Report cover image

Cell and Gene Therapy Deals Analysis, 2021-2024

Publisher Kalorama Information
Published Jun 01, 2024
Length 345 Pages
SKU # KLI18867385

Description

Cell and Gene Therapy Deals Analysis, 2021-2024


Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is published in two installments, the first in Q2 2024 and the second in Q4 2024. Customers who purchase the report will receive both installments.

Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and stakeholders looking to understand and leverage the trends shaping this burgeoning field.

No report published by a major market research publisher has tackled the cell and gene therapy dealmaking space more comprehensively. With cell and gene therapy is becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.

Why This Report?

With over 1,500 companies actively involved in the cell and gene therapy space, understanding the trends and competitive landscape is crucial for strategic planning. Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 provides the essential market analysis needed to navigate and capitalize on the opportunities within this fast-growing industry.

Report Highlights:
  • Quarterly Funding Trends (Q1 2021-Q1 2024): Graphical representation of funding amounts, showcasing investment influx in cell and gene therapy.
  • Deal Types: Comprehensive categorization of 2000+ deals, including venture capital, private investments, mergers, acquisitions, strategic collaborations, licensing, manufacturing/ supply, and distribution/ co-marketing.
  • Top Deal-Makers: Identification of the most active companies by deal type and overall deal activity.
  • Regional Deal Breakdown: Percentage analysis of deal-making activities across different regions.
Who Should Buy This Report

Understanding the volumes of deals that have been made, who is making which type and how many, and the deals' details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.

Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.

The following is just some of the information in this report:
  • Quarterly Funding Amounts Q1 2021- Q1 2024 by Type and Region
  • Specific details of 2000+ CGT Deals
  • Venture Capital/Private Funding Round Amounts, By Quarter
  • Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
  • Deals by Type – Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
  • Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
  • Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)
Methodology

The report’s insights are derived from a blend of primary and secondary research, including interviews with industry professionals, comprehensive literature reviews, and analysis of company and government reports.

Table of Contents

345 Pages
    • Introduction
    • $35 Billion in Investment in 2023
    • Quarterly Funding Amounts
    • Quarterly Funding Category Shares, Q1 2021 Through Q1 2024
    • Most Active Companies
    • VC/Private Funding in Flux
    • Strategic Investments in Cell and Gene Therapy
    • North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
    • Growing Numbers of M&A, Despite Lower Average Value
    • CGT Market Sees a Broad Variety of Collaborations
    • Stable Levels of Licensing in the Cell and Gene Therapy Market
    • Major Growth in Manufacturing and Supply Chain Management Activity in CGT
    • A Look at CGT Distribution and Co-Marketing Deals
    • A Look at Other Types of Deals Impacting Cell and Gene Therapy

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us